In the SELECT trial, 8,803 adults with overweight or obesity and preexisting cardiovascular disease received 2.4 mg of semaglutide weekly. In the matched placebo arm, 8,801 adults received placebo. Over a mean follow-up of 39.8 months, 569 patients in the semaglutide arm had a major adverse cardiovascular event; in the placebo arm, 701 did. The hazard ratio was 0.80. Permanent discontinuation of the trial product, mostly for gastrointestinal adverse events, occurred in 16.6 per cent of the semaglutide arm and 8.2 per cent of the placebo arm.
That is the central fact. It is worth beginning from it rather than from the cultural noise that surrounds it. SELECT is the first placebo-controlled outcomes trial to show that pharmacotherapy for weight reduction, in adults with overweight or obesity and in the absence of diabetes, reduces the risk of cardiovascular events. Published in The New England Journal of Medicine in December 2023, it remains the single most consequential dataset in the GLP-1 discussion.
The finding has been embedded almost immediately in a much broader cultural claim. The medications are now routinely described, in venues ranging from longevity podcasts to weekend magazine profiles, as the first serious pharmacological longevity intervention. That framing is not supported by the evidence. It is worth explaining why without diminishing what the evidence does support.
WHAT THE EVIDENCE SHOWS
Three bodies of trial evidence matter here. First, in patients with type 2 diabetes, a meta-analysis published in The Lancet Diabetes & Endocrinology in 2021 pooled eight cardiovascular outcomes trials covering 60,080 patients. It reported a twelve per cent reduction in all-cause mortality, an eleven per cent reduction in hospital admission for heart failure, and a twenty-one per cent reduction in a composite kidney outcome. The implication is specific: in patients with type 2 diabetes at elevated cardiovascular risk, GLP-1 receptor agonists reduce hard endpoints.
Second, in patients with overweight or obesity and established cardiovascular disease but without diabetes, SELECT demonstrated a roughly twenty per cent reduction in the MACE composite. This is a population the class had not previously been studied in at scale. The finding extended the evidence base from diabetes into a metabolic population with fewer formal diagnostic features, which is a meaningful expansion.
Third, a growing body of evidence now examines heart failure with preserved ejection fraction, kidney outcomes, and specific sub-populations. Across meta-analyses and follow-on studies published through 2024 and 2025, the pattern is consistent: across several at-risk populations, the class reduces MACE, reduces all-cause mortality, and improves several renal and cardiac endpoints. Within its bounds, the evidence is substantial and persuasive.
WHAT THE EVIDENCE DOES NOT SHOW
It is equally important to say what the evidence has not shown, because the gap is the point. No randomised trial of any GLP-1 medication has enrolled a population of generally healthy adults, followed them for life or for a substantial fraction of it, and reported a lifespan endpoint. The trials that exist are event-reduction trials in populations already at elevated risk. They are not lifespan trials. The distinction is not technical. Whether a drug extends lifespan in healthy populations is a different question from whether it reduces events in people who are already ill, and the evidence required to answer it is different.
Two further cautions follow. The discontinuation rate in SELECT, 16.6 per cent, roughly double the placebo rate, is not a peripheral safety note. It describes how the class is tolerated under trial conditions, and it bears on what a real-world, lifetime-horizon commitment to the medication would actually look like. The mechanism question is also unresolved. Several analyses, including prespecified work on the SELECT cohort, suggest that the cardiovascular benefit is not fully explained by weight loss or glucose lowering. Some fraction may come from direct vascular, inflammatory, or other systemic effects. That is interesting. It is not settled. The claim that GLP-1 medications act directly on biological mechanisms of ageing is not supported by current human trial evidence.
A CATEGORY PROBLEM
A drug that reduces cardiovascular events in adults with overweight and established cardiovascular disease is a meaningful clinical advance. It is not the same thing as a longevity drug, and treating it as one obscures the question longevity science actually has to answer.
The category error matters because the evidence is genuinely good. The strongest temptation in consumer longevity discourse is to take a strong finding in a defined clinical population and expand it into a larger claim about lifespan itself. But the evidence does not license that extrapolation. It licenses a narrower conclusion, and the specificity of that conclusion is the thing to hold.
WHAT THE EVIDENCE SUPPORTS, AND WHAT IT DOES NOT
What the evidence supports is already important enough: reduction of all-cause mortality in patients with type 2 diabetes at elevated cardiovascular risk; reduction of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease who do not have diabetes; and improvement in several renal and heart-failure endpoints across defined populations. These are clinical findings of real consequence, sourced from trials with clear endpoints and substantial statistical power.
What the evidence does not yet support is equally clear: lifespan extension in healthy populations; long-horizon safety and tolerability as a lifetime intervention; or a demonstrated direct effect on biological mechanisms of ageing independent of weight, glucose, and cardiovascular risk reduction. Those are the claims that require different trials, and those trials have not been conducted. The first set is a substantial clinical advance. The second remains the frontier. Holding the two apart is the discipline the subject still requires.
PRIMARY SOURCES
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine, 2023.
- Sattar N, Lee MMY, Kristensen SL, et al. “Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.” Lancet Diabetes & Endocrinology, 2021.
